Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr-Jun;13(2):163-171.
doi: 10.4103/jpbs.JPBS_498_20. Epub 2021 May 26.

A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy

Subodh Kumar  1 , Manoj K Saurabh  1 , Vikas Maharshi  1 , Dibyajyoti Saikia  2
Affiliations
Review

A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy

Subodh Kumar et al. J Pharm Bioallied Sci. 2021 Apr-Jun.

Abstract

Purpose: A number of research articles has been published evaluating safety and efficacy of drugs against COVID-19. This study was undertaken to collate and review the information regarding common proposed anti- viral drugs for easy reference.

Methods: The literature was search was done using terms like severe acute respiratory syndrome or SARS-CoV-2 or 2019-nCoV or SARS-CoV or COVID-19 in combination with drugs or treatment or pharmaco-therapy using PubMed and google scholar to identify relevant articles.

Results: Despite showing good early results, hydroxychloroquine and lopinavir-ritonavir has not shown clinical benefit in randomized controlled trials. However lopinavir in combination with other drugs specially interferon is being investigated. Remdesivir has shown positive effect in terms of clinical improvement and continued to being investigated alone or in combination with other drugs. Favipiravir has shown mixed results and more data from adequately powered study is needed to prove its efficacy.

Conclusions: Many drugs which showed positive effect in initial studies could not replicate the same benefit in large randomized controlled trials. There is need to evaluate efficacy and safety of drugs based on high quality evidence before allowing it to be used in general population.

Keywords: COVID-19; favipiravir; hydroxychloroquine; lopinavir-ritonavir; pharmacotherapy; remdesivir.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. World Health Organization. Solidarity clinical trial for COVID-19 treatment. [Last accessed on 2020 Aug 30]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-r... .
    1. University of Oxford. RECOVERY: Randomized Evaluation of COVID-19 Therapy. [Last accessed on 2020 Aug 30]. Available from: https://www.recoverytrial.net/
    1. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe covid-19 patients with tocilizumab. Proc Natl Acad Sci u s a. 2020;117:10970–5. - PMC - PubMed
    1. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in covid-19: a single center experience. j Med Virol. 2020;92:814–8. - PMC - PubMed
    1. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe covid-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in brescia, Italy. Autoimmun Rev. 2020;19:102568. - PMC - PubMed